| |
Konjac-mannan (glucomannan) improves glycemia and other associated risk
factors for coronary heart disease in type 2 diabetes. A randomized
controlled metabolic trial.
Diabetes Care. 1999 Jun;22(6):913-9.
Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E,
Brighenti F, Josse R, Leiter LA, Bruce-Thompson C.
Department of Nutritional Sciences, St. Michael's Hospital, Faculty
of Medicine, University of Toronto, Ontario, Canada. v.vuksan@utoronto.ca
OBJECTIVE:
To examine whether Konjac-mannan (KJM) fiber improves metabolic control
as measured by glycemia, lipidemia, and blood pressure in high-risk
type 2 diabetic patients.
RESEARCH DESIGN AND METHODS:
A total of 11 hyperlipidemic and hypertensive type 2 diabetic patients
treated conventionally by a low-fat diet and drug therapy participated.
After an 8-week baseline, all were randomly assigned to take either
KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan)
or matched placebo wheat bran fiber biscuits during two 3-week treatment
phases separated by a 2-week washout period. The diet in either case
was metabolically controlled and conformed to National Cholesterol Education
Program Step 2 guidelines, while medications were maintained constant.
Efficacy measures included serum fructosamine, lipid profiles, apolipoproteins,
blood pressure, body weight, and nutritional analysis.
RESULTS:
Compared with placebo, KJM significantly reduced the metabolic control
primary end points: serum fructosamine (5.7%, P = 0.007, adjusted alpha
= 0.0167), total:HDL cholesterol ratio (10%, P = 0.03, adjusted alpha
= 0.05), and systolic blood pressure (sBP) (6.9%, P = 0.02, adjusted
alpha = 0.025). Secondary end points, including body weight, total,
LDL, and HDL cholesterol, triglycerides, apolipoproteins A-1, B, and
their ratio, glucose, insulin, and diastolic blood pressure, were not
significant after adjustment by the Bonferroni-Hochberg procedure.
CONCLUSIONS:
KJM fiber added to conventional treatment may ameliorate glycemic control,
blood lipid profile, and sBP in high-risk diabetic individuals, possibly
improving the effectiveness of conventional treatment in type 2 diabetes.
Publication Types:
Clinical Trial
Randomized Controlled Trial
|